Research Article ISSN 2689-1050

Chemical & Pharmaceutical Research

Beyond Survival: Addressing the Long-Term Effects of Chemotherapy in Underserved Populations

Natalie Brin* and Yashwant Pathak

University of South Florida, Florida, USA.

***Correspondence:**
Natalie Brin, University of South Florida, Florida, USA.

Received: 01 June 2025; **Accepted:** 01 July 2025; **Published:** 11 July 2025

Citation: Natalie Brin, Yashwant Pathak. Beyond Survival: Addressing the Long-Term Effects of Chemotherapy in Underserved Populations. Chem Pharm Res. 2025; 7(3): 1-8.

Keywords
Chemotherapy, Cancer, Abnormal cells, Emotional distress.

Introduction

Cancer continues to be one of the leading causes of premature death worldwide, accounting for nearly 10 million deaths each year, with its prevalence increasing in both developed and developing nations [1]. Not only does the disease impact those diagnosed, but also families, caregivers, and entire healthcare systems. Throughout the past several decades, there have been significant advancements in cancer detection and treatment, especially chemotherapy, which have contributed to improved survival rates and longer life expectancy. These treatments have enabled most cancers to shift from a terminal diagnosis to a chronic and manageable condition for many [2]. However, this progress comes with a significant cost that remains under-addressed, especially in vulnerable populations. Survivors, especially those who undergo chemotherapy, often face a lifetime of physical complications, emotional distress, and financial strain [3].

At its core, cancer is a disease characterized by the uncontrollable division and growth of abnormal cells. Unlike healthy cells that grow, divide, and die in its regulated cycle, cancer cells bypass these regulatory mechanisms, continuing to proliferate even when not needed, often forming tumors and invading surrounding tissues. This uncontrolled proliferation results from genetic mutations and epigenetic changes that disrupt normal cellular signaling pathways [4]. The ability of cancer cells to replicate rapidly and resist their programmed cell death underlies both the severity of the disease and the challenges of achieving effective treatment.

First developed as a formal cancer treatment in the mid-20th century, chemotherapy has evolved into a standard therapeutic approach for a wide range of malignancies. Chemotherapy effectively shrinks tumors by targeting rapidly dividing cells, eliminating micrometastatic disease [5]. However, its non-selective nature also harms healthy cells during this process. Because of this, many cancer survivors experience a variety of physical and psychological side effects that can persist long after their active treatment ends [3].

The growing population of cancer survivors has brought more attention to the concept of survivorship. For many of these individuals, life after cancer consists of chronic fatigue, infertility, cognitive changes, neuropathy, and even an increased risk of secondary cancers. These challenges of post-treatment life are even more abundant in geographically isolated communities, where access to specialized care and rehabilitation services is very limited [6]. These communities often face systemic barriers such as inadequate transportation, financial instability, and lack of nearby cancer centers – all of which interfere with the ability to manage their long-term health needs [7].

Before beginning treatment, many patients and physicians will still consider if chemotherapy's anticipated benefits outweigh its potential for prolonged side effects and diminished quality of life – even if chemotherapy will successfully treat the disease. In fact, research has shown that some patients are hesitant to undergo chemotherapy in fear of these side effects, unless a significant survival benefit is guaranteed [8]. Better understanding and mitigating chemotherapy's long-term consequences, while addressing disparities in care access for rural and underserved populations, is essential to improving the overall cancer survivorship experience.

Long-Term Physical Health Effects of Chemotherapy

Even though chemotherapy is frequently viewed as a temporary phase of cancer treatment, its effects on the human body can

last for many years - or even a lifetime. The severe side effects, both during and after treatment, occur as a result of the cytotoxic drugs that do not distinguish between malignant and healthy rapidly dividing cells. One of the most common symptoms that can linger for years after remission is fatigue. This can affect work performance, participation in daily activities, and overall energy levels [9]. Another common side effect of treatment is chemotherapy-induced peripheral neuropathy, which causes tingling, numbness, or pain in the hands and feet – interfering with one's mobility and overall quality of life [10].

Heart complications are another long-term consequence of certain chemotherapeutic agents. For example, even though drugs like anthracyclines and trastuzumab have been found to be effective against cancer cells, they also have been linked to issues like arrhythmias and heart failure [11]. Some of these complications can emerge years after treatment, requiring lifelong cardiac monitoring and interventions. Additionally, cancer treatments can result in severe damage to an individual's immune system, especially for patients who received high-dose chemotherapy or bone marrow transplants [12]. This damage can leave survivors more susceptible to infections and inflammatory conditions for the rest of their life.

Alongside these complications, malnutrition remains a significant yet frequently overlooked long-term issue among chemotherapy patients. The treatment often leads to persistent nausea, vomiting, and appetite loss, which can severely compromise a patient's nutritional intake, increasing the risk of malnutrition both during and after treatment. This can eventually lead to chronic malnourishment, increasing susceptibility to infections, delaying tissue regeneration, and impairing overall physical function. Long-term malnutrition has also been associated with reduced treatment efficacy and overall lower survival rates, highlighting the importance of early nutritional assessment and intervention throughout and after the course of chemotherapy [13].

The age at which a patient receives chemotherapy can play a significant role in long-term outcomes. To be more specific, the effects of treatment on pediatric patients are often amplified since their bodies and organ systems are still developing. Children who survive cancer may experience hormonal imbalances, growth delays, and musculoskeletal impairments that persist into adulthood [14]. Regarding adolescents and young adults, they tend to report lower quality of life in comparison to their peers without cancer, which is likely because of the ongoing physical limitations and psychological distress resulting from their treatment history [15]. On the other hand, adult survivors face a higher risk of developing treatment-related health issues, especially with increasing age. This includes, but is not limited to, pulmonary dysfunction, cardiovascular disease, and secondary malignancies – all of which can negatively impact an individual's quality of life as they progress through adulthood [16].

In some cases, chemotherapy can cause irreversible damage to organs such as the heart and lungs, especially when combined with other treatments like surgery [10]. While this combination can be lifesaving, especially for solid tumors, it can result in severe physical consequences. Surgical interventions can be very invasive as they may involve partial or complete removal of organs, limb amputations, or reconstructive procedures that alter body function and appearance. Many complications can arise from these types of surgeries; this includes an increased risk for infection, delayed healing, and may even contribute to cancer recurrence by triggering inflammatory responses that encourage tumor growth [17]. The patients that undergo both chemotherapy and invasive surgery tend to require extended rehabilitation, but these services are not always available, especially for those in medically underserved areas.

Geographic disparities play a huge role in the post-treatment outcomes for cancer survivors. Unfortunately, individuals that reside in rural areas often face limited access to cancer treatment resources, including rehabilitation specialties, long-term care facilities, and even basic access to oncologists. This lack of proximity to adequate healthcare infrastructures means that many survivors end up without any form of follow-up care, allowing chronic side effects to go unmanaged and potentially worsen over time [18]. Additionally, access to physical therapy, nutritional counseling, and pain management – all factors essential to the restoration of function and strength – can be scarce or even nonexistent in medically underserved regions [19].

The development of today's technology potentially offers promising solutions for extending healthcare to these communities. Telemedicine platforms provide a way for patients to connect to specialties without requiring long-distance travel. Similarly, mobile health clinics that are equipped with diagnostic tools and trained staff can be a great option for follow-up services that can be delivered directly to patients' homes [20]. These models of care can be very valuable in areas where geographic and economic barriers make it difficult for patients to remain involved with the healthcare system.

Efforts to reduce disparities in long-term care must also include systemic change. Some changes that can bridge this gap include expanding rural healthcare infrastructure, investing in survivor-specific care programs, and offering loan forgiveness and incentives for oncology professionals to practice in underserved areas. Research has shown that increased access to follow-up services for cancer survivors can significantly improve long-term outcomes and quality of life [21].

Chemotherapy has undoubtedly played a huge role in advancing the fight against cancer, but its long-term effects on survivors remain a serious issue that needs to be addressed, especially for patients in rural and underserved communities with limited access to continued care. By recognizing and responding to these concerns, the healthcare system can ensure that survival does not come at the cost of long-term suffering.

Mental Health Implications for Cancer Survivors

While the physical effects of chemotherapy are widely recognized, the psychological consequences are often less apparent yet equally

significant. It is very common for cancer survivors to experience a range of mental health challenges both during and long after treatment has ended. Some of these symptoms include anxiety, depression, sleep disturbances, and post-traumatic stress disorders. These issues tend to arise as a result of the trauma of the cancer experience but also the physiological effects of chemotherapy itself, like hormone disruption, inflammation, and neurotoxicity [22].

One of the most common cognitive side effects of treatment is "chemo brain," a term used by survivors to describe mental fog, reduced concentration, and memory lapses. Although initially underestimated, research now confirms that chemotherapy does indeed affect brain function through a variety of pathways, leading to both short- and long-term neurocognitive impairments [23]. The variety of symptoms resulting from chemotherapy can interfere with one's ability to work, maintain relationships, and even perform daily tasks, which increase feelings of helplessness or frustration for survivors.

Mental health disparities are particularly evident in rural and underserved communities. Their limited access to licensed mental health professionals, lack of insurance coverage, and long wait times often make it quite difficult for survivors to obtain the psychological support they need [24]. In fact, many rural regions do not have any mental health providers at all, forcing individuals to rely solely on their primary care physicians – who may lack the time or training to address the complex emotional needs of a cancer survivor [25].

Unfortunately, access to mental health providers does not necessarily guarantee care, as financial challenges can limit service use. After patients face the economic strain of cancer treatment, many survivors are unable to afford the additional expenses of post-treatment mental healthcare due to the high cost of therapy, prescription medications, and transportation [26]. Research indicates that the cost-related stress of cancer treatment can lead to a variety of mental health problems and overall psychological distress.

Children and adolescents are also extremely vulnerable to these lasting mental health effects. Pediatric cancer survivors tend to struggle with feelings of isolation, fear of recurrence, and developmental delays – all of which impact social and emotional growth. Regarding adult survivors, long-term psychological trauma can arise from concerns about one's body image, employment limitations, and fertility loss. No matter the age, survivors often report difficulty adjusting to day-to-day life after completion of treatment and they even frequently experience a loss of identity or sense of purpose [27].

Support systems are essential for the recovery of one's mental health. There are a variety of methods shown to improve emotional outcomes for cancer survivors – including peer support groups, telehealth-based counseling, and integrated survivorship programs. These approaches are especially beneficial to rural communities, since there is a limited number of in-person resources. Virtual platforms allow survivors to access a variety of care without the burden of travel or time off work. Some of these include one-on-one counseling, group therapy, educational materials, and community-based mental health initiatives – which have shown promising results in delivering culturally competent care to vulnerable populations [27].

In order to provide effective care for cancer survivors, the link between physical symptoms and mental health must be acknowledged. The fatigue, cognitive impairment, and chronic pain that comes with this diagnosis can significantly impact one's emotional well-being, which end up creating a cycle of distress that worsens overall health.

Financial Burdens and Healthcare Disparities in Rural and Underserved Populations

The financial toll of cancer extends far beyond just the cost of chemotherapy medications. Patients and survivors often face a variety of economic burdens – including, but not limited to, travel expenses, ongoing medical bills, lost income, and costs related to long-term care. For most individuals, these cumulative expenses lead to "financial toxicity", which refers to a condition that negatively impacts overall health outcomes and quality of life due to severe financial stress [28].

Even with partial insurance coverage, out-of-pocket costs may still be high. The extensive process of chemotherapy treatment includes laboratory tests, imagining procedures, multiple drugs, and hospital stays. Not only can these direct medical costs negatively impact the lives of patients, but indirect expenses like childcare, unpaid time off work, and the cost of home health aids, can consequently affect their lives as well. These factors can result in financial pressures that persist for years after treatment, especially survivors who continue to need physical therapy, medications, or specialist visits [29].

Cancer patients that come from rural and underserved areas experience an even greater financial impact. In fact, individuals residing in these areas are more likely to be uninsured or underinsured, less likely to be employed in jobs that offer paid leave or disability benefits, and they are also more likely to travel long distances for the care they need [30]. This combination of factors significantly increases their out-of-pocket costs, despite treatment being technically available.

The high cost of traveling far distances for adequate treatment alone can prevent rural patients from receiving timely or consistent care. Depending on the type of treatment, it can require transportation, lodging, many missed workdays, and multiple visits to distant cancer centers – all of which can add up quickly. These travel-related challenges can be very difficult for rural patients to manage, especially for those with mobility issues, limited transportation options, or responsibilities as primary caregivers [31]. Because of this, many individuals may delay or abandon treatment entirely, resulting in overall worse health outcomes.

Disparities in healthcare infrastructure also contribute to financial strain. For instance, many rural areas lack access to comprehensive cancer centers, clinical trials, and specialized services like reconstructive surgery, fertility preservation, and genetic counseling [32]. Even if patients are able to receive chemotherapy at their local hospitals, they still may lack nearby access to follow-up care, survivorship programs, and mental health services. This means that they would need to pay even more out of pocket to travel to urban centers in order to access the services they need [33].

Socioeconomic inequalities also play a role in the accessibility to advanced and personalized treatment. For example, research has shown that patients that come from lower-income backgrounds are less likely to receive targeted therapies, biomarker tests, or participate in clinical trials [34]. This disparity is primarily due to awareness gaps, cost, and systemic barriers, which not only affect individual outcomes but also reinforces broader patterns of inequality in patient care.

Effective policy interventions are essential to mitigating these burdens. For example, studies show that the expansion of Medicaid has led to increased access to cancer screenings, earlier diagnosis, and improved insurance coverage among cancer patients in underserved areas [35]. Financial assistance programs that help individuals cover travel, lodging, and treatment-related costs can also make a significant difference, especially when they are designed to address the specific challenges faced by rural communities.

In order to achieve long-term improvements in cancer survivorship outcomes, it is important to address both the economic and structural challenges that influence access to care. Increasing federal and state funding for rural cancer programs, supporting local cancer navigation services, and expanding community health initiatives can help close the gap in care. These efforts ensure that all patients – not just those in well-resourced areas – have access to affordable, high-quality treatment.

The Role of Genetic Testing & Personalized Care

Genetic testing has become an essential element of the oncology field. This type of testing has been found to provide valuable insight into cancer prevalence as well as treatment effectiveness. Historically, it was primarily utilized to identify the risks of hereditary cancers, but nowadays its role has expanded to also guide therapeutic decisions and minimize long-term toxicity. This provides a more personalized approach, which offers the potential to reduce adverse effects and improve survivorship outcomes for chemotherapy patients [36].

A subset of genetic testing, called pharmacogenomics, allows oncologists to tailor chemotherapy regimens to individual patients based on how their bodies metabolize to specific drugs. For instance, identifying genetic variations in drug-metabolizing enzymes can help predict which patients may suffer severe side effects or respond poorly to treatment. Having this information allows clinicians to adjust doses or selective alternative agents that are better suited to the specific patient [37]. Not only do these new strategies improve treatment efficacy, but they also help avoid preventable long-term complications, like neuropathy or organ damage.

However, accessibility to genetic testing still remains limited to geographically isolated communities. Unfortunately, these vulnerable populations face obstacles related to cost, lack of awareness about testing options, and limited availability of genetic counselors [38]. These disparities in healthcare mean that many patients are treated without taking into account their personalized data, which could improve both short and long-term outcomes.

Cultural and socioeconomic factors further complicate access to personalized care. In areas where resources are limited, patients may face concerns regarding privacy, stigma, or the implications of positive test results for their families. A global review revealed that both ethical and cultural barriers can significantly impact the uptake of genetic testing in low- and middle-income populations, as well as in rural regions of high-income countries [39]. These results highlight the need for culturally sensitive counseling while building trust in healthcare providers and systems.

Initiatives to improve access include expanding telehealth-based genetic counseling and incorporating testing services within community clinics. These approaches increase accessibility without the need for extensive travel. Additionally, policy changes that expand insurance coverage for genetic testing as well as counseling could remove financial barriers that disproportionately affect underserved populations [38,39].

The continued integration of pharmacogenomics into routine cancer care offers significant potential to reduce toxicity, improve survival rates, and promote equity in treatment delivery. As research advances and costs decline, prioritizing access to these tools for all populations must remain a priority.

Advances in Drug Discovery & Pharmaceutical Innovations

Decades of reliance on cytotoxic chemotherapy have led to significant advancements in cancer treatment, but they have also revealed the long-term harms survivors endure. Because of this, oncology researchers have been working towards the development of drugs that are both more effective and less toxic. The overall goal of these innovations is to reduce the chronic side effects that result from traditional chemotherapy while improving survival rates and quality of life [40].

One major area of advancement in this field is the development of chemoprotective agents. These drugs, like BNP7787, have shown potential to reduce damage to healthy tissue without compromising its cancer-fighting efficacy. In fact, studies have indicated that BNP7787 may help delay or prevent the development of neuropathy and renal toxicity, which are two of chemotherapy's most debilitating long-term complications [40].

Immunotherapy and biologic agents have also become increasingly utilized as alternatives or complements to chemotherapy, as they activate the body's immune system and provide a more targeted and tolerable approach. For example, combination immunotherapy has shown promising results in treating recurrent or refractory CNS lymphomas, expanding possibilities for patients with limited treatment options [41]. Furthermore, by integrating immunotherapy with chemotherapy, this may enhance treatment outcomes while also lowering toxicity when doses are reduced [42].

Despite these advancements, accessibility continues to be a significant challenge for patients in resource-limited regions. Inadequate clinical trial infrastructure, exclusion from trials with advanced therapies, and a shortage of oncology specialists in these areas hinder equitable care and contribute to ongoing disparities in care and treatment outcomes [43].

Digital health tools, like mobile applications and telemedicine platforms, can help bridge this gap. These technologies allow patients to connect with specialists and learn about clinical trial opportunities from their homes, increasing engagement among underserved populations [44].

Cost is another major barrier that prevents these communities from accessing these pharmaceutical innovations. The development of new cancer drugs is resource-intensive, leading to higher prices that limit accessibility even after approval [45]. This financial strain is especially challenging for patients without comprehensive insurance, many of whom are already burdened by the expenses associated with standard chemotherapy.

In order to improve access for all cancer patients, policy interventions such as expanding rural clinical trial sites, increasing insurance coverage, and encouraging trial participation need to be implemented. Reducing disparities in access to emerging therapies is essential to ensure that advancements in cancer treatment benefit all survivors—not just those in urban or well-resourced areas.

The Need for a Multidisciplinary Approach in Cancer Care

Due to the increasing complexity of survivorship care, it is clear that no single provider can meet all the long-term needs of a cancer patient. Survivors may experience a variety of physical side effects, along with nutritional deficits, mental health challenges, and social barriers that require coordinated management. Therefore, it is essential to incorporate a multidisciplinary approach that integrates professionals from various specialties in order to deliver comprehensive and effective survivorship care [46].

This model improves symptom management and reduces fragmentation for patients by utilizing tailored care plans, emphasizing holistic recovery, and enhancing communication between providers. For example, embedding mental health services into cancer care helps address depression, anxiety, and trauma – critical issues that are often overlooked in standard follow-ups [47]. Similarly, involving nutritionists in care plans can prevent or address malnutrition, another concern that frequently goes unnoticed during and after treatment.

Unfortunately, rural patients face significant barriers when trying to access this multidisciplinary model of care. Many of these individuals live far from specialists, and their primary care physicians may lack oncology training as well. As a result, cancer survivors residing in these regions often receive fragmented and limited access to essential services for managing long-term complications [47]. This lack of coordination increases the risk of hospital readmissions, untreated side effects, and an overall lower quality of life.

Telemedicine offers a promising solution to these underserved populations. It gives patients the opportunity to have access to a multidisciplinary team by connecting them to remote oncology and specialty teams. Virtual consultations with oncologists, dietitians, or therapists help reduce delays and travel-related stress in communities that lack these resources [48].

Community-based survivorship programs are another promising approach to bridging gaps in long-term cancer care. These programs incorporate care coordination within local settings and provide continuous support through education about the late effects of treatment, regular check-ins, and assistance in overcoming barriers to care. For instance, a breast cancer community program demonstrated that having structured support can improve patient monitoring and increase survivors' confidence in managing their health post treatment [49].

Given the growing importance of survivorship care, it is essential that all patients – regardless of geographic location – have access to integrated, team-based care. Expanding funding for telehealth services, investing in community survivorship programs, and offering incentives to grow the healthcare workforce can collectively strengthen care coordination and improve outcomes for survivors in rural and underserved areas.

Future Solutions and Policy Recommendations

The growing population of cancer survivors highlights the critical need for systemic reforms that go beyond initial treatment to encompass long-term survivorship care. Effectively addressing the physical, mental, and financial challenges associated with recovery – especially in rural and underserved areas – requires proactive, comprehensive strategies. Key priorities include infrastructure improvements, insurance reforms, workforce incentives, and investing in inclusive research to promote equity across populations.

One of the most urgent needs is increased government support for rural healthcare systems. Many rural hospitals and clinics face shortages in funding, staff, and medical resources needed to provide adequate follow-up services. Federal initiatives aimed at underserved regions can help close these gaps, drawing from successful models like the federal rural health initiative [50]. Continued investment in rural health infrastructure is crucial to extending high-quality survivorship care to geographically

isolated communities.

Encouraging healthcare providers to practice in underserved areas is another vital solution that helps expand access to survivorship care. Incentives like loan repayment programs, housing assistance, and career development programs can help attract oncologists, mental health professionals, nurses, and genetic counselors to regions with the greatest provider shortages [51]. Strengthening the workforce in these areas can reduce wait times, enhance care continuity, and facilitate the delivery of multidisciplinary services.

Insurance coverage also plays an important factor in shaping access to survivorship care. Studies have shown that the expansion of Medicaid and other similar programs is associated with increased utilization of preventative services, earlier diagnoses, and better follow-up care for cancer survivors [35]. To ensure comprehensive recovery, coverage should be expanded to include long-term services such as mental health support, fertility preservation, physical therapy, genetic counseling, and nutritional guidance – components of recovery that are often overlooked or underfunded.

Complementary therapies such as acupuncture, massage, and mindfulness-based stress reduction have shown benefits alleviating pain, fatigue, and anxiety, especially within palliative care settings [52]. Incorporating these into publicly funded cancer programs can provide survivors with additional options for managing chronic symptoms. Another overlooked financial burden is the cost of oral chemotherapy wastage; strategies like medication recycling or prescribing smaller quantities can reduce waste and improve affordability [53].

Increasing diversity in cancer research is also crucial for closing outcome gaps, as minority and underserved populations are continuously underrepresented in clinical trials. Prioritizing community outreach, transportation assistance, and culturally tailored education can increase participation and ensure that new treatments benefit all groups [54].

A comprehensive policy agenda rooted in health equity must address the long-term effects of chemotherapy by expanding insurance coverage, improving infrastructure, strengthening the oncology workforce, and promoting inclusive research – ensuring that every survivor receives the care they need, regardless of their geographic location or socioeconomic background.

Conclusion

While chemotherapy has significantly improved cancer survivor rates, its long-term consequences demand equal attention. Many survivors continue to face physical complications such as fatigue, organ damage, neuropathy, along with psychological complications like anxiety, depression, and cognitive impairment [55]. These burdens are especially pronounced in rural and underserved communities, where there is limited access to follow-up care, mental health services, and financial support [56].

These persistent disparities highlight the urgency for a more comprehensive and equitable survivorship model of care. Expanding access to genetic testing, investing in personalized and less toxic drug treatments, and incorporating multidisciplinary care teams are critical steps towards improving long-term outcomes [57]. Policy efforts must also focus on increasing healthcare access, enhancing provider distribution, and ensuring that all survivors receive the support they need for lasting recovery.

The future of cancer care depends not only on curing the disease but also on managing the lasting effects it leaves behind. Through continued innovation, policy reform, and a strong dedication to equity, survivorship can become not just a temporary phase of care, but a lasting foundation for lifelong health.

References

1. Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021; 127: 3029-3030.
2. Frei III E. Curative cancer chemotherapy. Cancer Res. 1985; 45: 6523-6537.
3. Love RR, Leventhal H, Easterling DV, et al. Side effects and emotional distress during cancer chemotherapy. Cancer. 1989; 63: 604-612.
4. Hausman DM. What is cancer?. Perspect Biol Med. 2019; 62: 778-784.
5. Young RC. Mechanisms to improve chemotherapy effectiveness. Cancer. 1990; 65: 815- 822.
6. Amber Bourgeois, Tara Horrill, Ashley Mollison, et al. Barriers to cancer treatment for people experiencing socioeconomic disadvantage in high- income countries: a scoping review. BMC Health Serv Res. 2024; 24: 670.
7. Wercholuk AN, Parikh AA, Snyder RA. The road less traveled: transportation barriers to cancer care delivery in the rural patient population. JCO Oncol Pract. 2022; 18: 652-662.
8. Vaz Luis I, Neill AO, Sepucha K, et al. Survival benefit needed to undergo chemotherapy: patient and physician preferences. Cancer. 2017; 123: 2821-2828.
9. Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer. 2008; 112: 2577-2592.
10. Craig Carr, Julia Ng, Tim Wigmore. The side effects of chemotherapeutic agents. Current Anaesthesia & Critical Care. 2008; 19: 70-79.
11. Monsuez JJ, Charniot JC, Vignat N, et al. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010; 144: 3-15.
12. Klener P. Chemotherapy side effects and their management. In Supportive Care In Cancer. 1999; 297-313.
13. Davidson W, Teleni L, Muller J, et al. Malnutrition and chemotherapy-induced nausea and vomiting: implications for practice. Oncol Nurs Forum. 2012; 39: 340-345.
14. Hoffman MC, Mulrooney DA, Steinberger J, et al. Deficits in physical function among young childhood cancer survivors. J Clin Oncol. 2013; 31: 2799-2805.

15. Maunsell E, Pogany L, Barrera M, et al. Quality of life among long-term adolescent and adult survivors of childhood cancer. J Clin Oncol. 2006; 24: 2527-2535.
16. Deimling GT, Sterns S, Bowman KF, et al. The health of older-adult, long-term cancer survivors. Cancer Nurs. 2005; 28: 415-424.
17. Beecher SM, O'Leary DP, McLaughlin R, et al. The impact of surgical complications on cancer recurrence rates: a literature review. Oncol Res Treat. 2018; 41: 478-482.
18. Pedro LW, Schmiege SJ. Rural living as context: a study of disparities in long-term cancer survivors. Oncol Nurs Forum. 2014; 41: 211-219
19. Aziz NM. Cancer survivorship research among ethnic minority and medically underserved groups. Oncol Nurs Forum. 2002; 29: 789-801.
20. Morris BB, Rossi B, Fuemmeler B. The role of digital health technology in rural cancer care delivery: a systematic review. J Rural Health. 2022; 38: 493-511.
21. Belasco EJ, Gong G, Pence B, et al. The impact of rural health care accessibility on cancer-related behaviors and outcomes. Appl Health Econ Health Policy. 2014; 12: 461-470.
22. Cull A. Psychological aspects of cancer and chemotherapy. J Psychosom Res. 1990; 34: 129-140.
23. Zare A, Bahia NJ, Eidy F, et al. The relationship between spiritual well-being, mental health, and quality of life in cancer patients receiving chemotherapy. J Family Med Prim Care. 2019; 8: 1701-1705.
24. Mongelli F, Georgakopoulos P, Pato MT. Challenges and opportunities to meet the mental health needs of underserved and disenfranchised populations in the United States. Focus. 2020; 18: 16-24.
25. Morales DA, Barksdale CL, Beckel-Mitchener AC. A call to action to address rural mental health disparities. J Clin Transl Sci. 2020; 4: 463-467.
26. Gordon LG, Merollini KM, Lowe A, et al. A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient. 2017; 10: 295-309.
27. Hudson MM, Bhatia S, Casillas J, et al. Long-term follow-up care for childhood, adolescent, and young adult cancer survivors. Pediatrics. 2021; 148: e2021053127.
28. Karlsson G, Nygren P, Glimelius B. Economic aspects of chemotherapy. Acta Oncol. 2001; 40: 412-433.
29. Xu RH, Wang LL, Zhou LM, et al. Urban–rural differences in financial toxicity and its effect on cancer survivors' health-related quality of life and emotional status: a latent class analysis. Support Care Cancer. 2022; 30: 4219-4229.
30. Zahnd WE, Davis MM, Rotter JS, et al. Rural-urban differences in financial burden among cancer survivors: an analysis of a nationally representative survey. Supportive Care Cancer. 2019; 27: 4779-4786.
31. Desai A, Gyawali B. Financial toxicity of cancer treatment: moving the discussion from acknowledgement of the problem to identifying solutions. E Clinical Medicine. 2020; 20: 100269.
32. Virani S, Burke L, Remick SC, et al. Barriers to recruitment of rural patients in cancer clinical trials. J Oncol Pract. 2011; 7: 172-177.
33. Lin CC, Bruinooge SS, Kirkwood MK, et al. Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance. J Clin Oncol. 2015; 33: 3177-3185.
34. Norris RP, Dew R, Sharp L, et al. Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis. BMC med. 2020; 18: 1-12.
35. Nikpay SS, Tebbs MG, Castellanos EH. Patient Protection and Affordable Care Act Medicaid expansion and gains in health insurance coverage and access among cancer survivors. Cancer. 2018; 124: 2645-2652.
36. Eng C, Hampel H, Chapelle ADL. Genetic testing for cancer predisposition. Annual review of medicine. 2001; 52: 371-400.
37. Lee W, Lockhart AC, Kim RB, et al. powerful tools in cancer chemotherapy and drug development. Oncologist. 2005; 10: 104-111.
38. d'Agincourt Canning L. Genetic testing for hereditary cancer: challenges to ethical care in rural and remote communities. HEC Form. 2004; 16: 222-233.
39. Zhong A, Darren B, Loiseau B, et al. Ethical, social, and cultural issues related to clinical genetic testing and counseling in low-and middle-income countries: a systematic review. Genet Med. 2021; 23: 2270-2280.
40. Hausheer FH, Kochat H, Parker AR, et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol. 2003; 52: 3-15.
41. Ambady P, Szidonya L, Firkins J, et al. Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma. 2019; 60: 515-518.
42. Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy. 2015; 7: 309-316.
43. Mudaranthakam DP, Gajewski B, Krebill H, et al. Barriers to clinical trial participation: comparative study between rural and urban participants. JMIR cancer. 2022; 8: e33240.
44. Tarver WL, Haggstrom DA. The use of cancer-specific patient-centered technologies among underserved populations in the United States: systematic review. J Med Internet Res. 2019; 21: e10256.
45. Rubin EH, Gilliland DG. Drug development and clinical trials-the path to an approved cancer drug. Nat Rev Clin Oncol. 2012; 9: 215-222.

46. Ko C, Chaudhry S. The need for a multidisciplinary approach to cancer care. J Surg Res. 2002; 105: 53-57.
47. Levit LA, Byatt L, Lyss AP, et al. closing the rural cancer care gap: three institutional approaches. JCO Oncol Pract. 2020; 16: 422-430.
48. Eifel J. A multidisciplinary approach. Oncologic Imaging: A Multidisciplinary Approach E-Book: Expert Consult-Online and Print. 2012; 17.
49. Dietrich L, Smith AL, Watral A, et al. Effectiveness of a survivorship program: An assessment of patients with breast cancer in a community setting. J Oncol Pract. 2016; 12: e688-e696.
50. Martin ED. The federal initiative in rural health. Public Health Rep. 1975; 90: 291-297.
51. Lee DM, Nichols T. Physician recruitment and retention in rural and underserved areas. Int J Health Care Qual Assur. 2014; 27: 642-652.
52. Mansky PJ, Wallerstedt DB. Complementary medicine in palliative care and cancer symptom management. Cancer. 2006; 12: 425-431.
53. Monga V, Meyer C, Vakiner B, et al. Financial impact of oral chemotherapy wastage on society and the patient. J Oncol Pharm Pract. 2019; 25: 824-830.
54. Wallington SF, Dash C, Sheppard VB, et al. Enrolling minority and underserved populations in cancer clinical research. Am J Prev Med. 2016; 50: 111-117.
55. AK M. Cancer Chemotherapy-Solutions to the Problems it causes. InPharma. 1984; 7.
56. Hashmi SK, Geara F, Mansour A, et al. Cancer management at sites with limited resources: challenges and potential solutions. The Comprehensive Cancer Center. 2022; 18: 173-185.
57. Barot S, Patel H, Yadav A, et al. Recent advancement in targeted therapy and role of emerging technologies to treat cancer. Med Oncol. 2023; 40: 324.